Efficacy of Bifeprunox in Patients With Schizophrenia
A Multinational, Randomised, Double-blind, Fixed-dose, Bifeprunox Study Combining a 12-Week Placebo-controlled, Quetiapine-referenced Phase With a 12-month Quetiapine-controlled Phase in Patients With Schizophrenia
Sponsor: H. Lundbeck A/S
Terminated
Interim analysis showed inadequate efficacy of bifeprunox
A PHASE3 clinical study on Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by H. Lundbeck A/S and has accumulated 6 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lundbeck A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arkhangelsk, Russia , Bangkok, Thailand , Beijing, China , Brasov, Romania , Bucharest, Romania , Chiang Mai, Thailand , Chita, Russia , Hlevakha, Ukraine , Hualien Town, Taiwan , Iași, Romania and 13 more locations